Molecular Partners Ag Stock Performance
| MLLCF Stock | USD 2.25 0.00 0.00% |
The company secures a Beta (Market Risk) of -0.73, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Molecular Partners are expected to decrease at a much lower rate. During the bear market, Molecular Partners is likely to outperform the market. At this point, Molecular Partners has a negative expected return of -0.62%. Please make sure to verify Molecular Partners' maximum drawdown, as well as the relationship between the kurtosis and day typical price , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 133.7 M | |
| Total Cashflows From Investing Activities | -22.2 M |
Molecular |
Molecular Partners Relative Risk vs. Return Landscape
If you would invest 360.00 in Molecular Partners AG on November 18, 2025 and sell it today you would lose (135.00) from holding Molecular Partners AG or give up 37.5% of portfolio value over 90 days. Molecular Partners AG is currently producing negative expected returns and takes up 5.0113% volatility of returns over 90 trading days. Put another way, 45% of traded pink sheets are less volatile than Molecular, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Molecular Partners Target Price Odds to finish over Current Price
The tendency of Molecular Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.25 | 90 days | 2.25 | roughly 96.0 |
Based on a normal probability distribution, the odds of Molecular Partners to move above the current price in 90 days from now is roughly 96.0 (This Molecular Partners AG probability density function shows the probability of Molecular Pink Sheet to fall within a particular range of prices over 90 days) .
Molecular Partners Price Density |
| Price |
Predictive Modules for Molecular Partners
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Molecular Partners. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Molecular Partners' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Molecular Partners Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Molecular Partners is not an exception. The market had few large corrections towards the Molecular Partners' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Molecular Partners AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Molecular Partners within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.54 | |
β | Beta against Dow Jones | -0.73 | |
σ | Overall volatility | 0.61 | |
Ir | Information ratio | -0.13 |
Molecular Partners Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Molecular Partners for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Molecular Partners can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
Molecular Partners Fundamentals Growth
Molecular Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Molecular Partners, and Molecular Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Pink Sheet performance.
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (41.92 M) | |||
| Shares Outstanding | 36.04 M | |||
| Price To Earning | 1.74 X | |||
| Price To Book | 0.91 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| EBITDA | (60.67 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 5.15 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.82 X | |||
| Total Asset | 172.67 M | |||
About Molecular Partners Performance
By analyzing Molecular Partners' fundamental ratios, stakeholders can gain valuable insights into Molecular Partners' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Molecular Partners has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecular Partners has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 163 people.Things to note about Molecular Partners performance evaluation
Checking the ongoing alerts about Molecular Partners for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Molecular Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Molecular Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Partners' stock is overvalued or undervalued compared to its peers.
- Examining Molecular Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Partners' pink sheet. These opinions can provide insight into Molecular Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Molecular Pink Sheet analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |